Intuitive Surgical Inc. Form 4 Filings

Intuitive Surgical senior vice president Mark Brosius reported several equity compensation transactions. He received 2,793 performance stock units originally granted on February 28, 2023, after the company confirmed the required performance goals were achieved. These PSUs are scheduled to vest on February 28, 2026, subject to continued service.

He also received a new grant of 4,928 restricted stock units dated February 26, 2026, which vest 25% annually over four years. Previously granted RSUs from 2024 and 2025 partially vested, converting into 1,622 and 973 shares of common stock, with 805 and 483 shares respectively withheld at a price of $506.17 per share to cover statutory tax obligations.

Intuitive Surgical (ISRG) executive Myriam Curet reported option exercises, RSU vesting, and related share sales through a trust. On February 10, 2026, a trust associated with Curet acquired 838 common shares from vested RSUs and 105 shares via stock option exercise, and disposed of 417 shares to cover taxes. The trust also sold 105 shares at $494.65 on February 10 and 421 shares at $494.96 on February 11 in open-market transactions under a Rule 10b5-1 trading plan. Following these transactions, the trust held 409 common shares, while Curet directly held derivative positions including 1,257 stock options and 838 RSUs subject to the disclosed vesting schedules.

Intuitive Surgical officer Fredrik Widman, VP Corporate Controller, reported several equity transactions around restricted stock unit (RSU) vesting. On February 10, 2026, 567 RSUs converted into an equal number of common shares at an exercise price of $0.0, increasing his directly held common stock to 1,095 shares.

Also on February 10, 302 common shares were disposed of at $492.84 per share to cover statutory tax withholding, leaving 793 common shares directly owned. After these transactions, Widman held 567 RSUs directly.

On February 11, 2026, Widman executed an open‑market sale of 133 common shares at $494.96 per share under a pre‑established Rule 10b5‑1 trading plan that expires on May 21, 2026, resulting in 660 common shares directly owned.

Intuitive Surgical CEO David J. Rosa reported routine stock-based compensation activity. On February 10, 2026, 1,436 restricted stock units from a February 10, 2023 grant vested and converted into the same number of common shares at an exercise price of $0.0.

A portion of these shares, 724 common shares at $492.84 per share, was withheld to cover statutory tax obligations. After these transactions, Rosa directly holds 229,570 shares of Intuitive Surgical common stock. The RSUs vest in four equal annual installments of 25%, contingent on continued service.

Intuitive Surgical director Gary S. Guthart reported the vesting and settlement of 2,633 restricted stock units (RSUs) into an equal number of common shares on February 10, 2026. The RSUs vest 25% per year over four years starting February 10, 2023.

To cover statutory tax withholding on this vesting, 1,306 common shares were withheld at a value of $492.84 per share, leaving 5,021 common shares held directly after the transactions. In addition, Guthart has indirect beneficial ownership of common stock through trusts for a daughter, a son, and another trust.

Intuitive Surgical executive Gary Loeb, EVP & Chief Legal and Compliance, reported routine equity activity. On February 10, 2026, 315 restricted stock units vested and were converted into common stock on a one-for-one basis. A portion of the newly issued shares was withheld at a price of $492.84 per share to satisfy statutory tax obligations. After these transactions, Loeb beneficially owned 3,704 shares of common stock directly and 314 restricted stock units that remain subject to future vesting.

Intuitive Surgical (ISRG) senior vice president Iman Jeddi reported routine equity vesting and tax withholding transactions. On February 10, 2026, 838 restricted stock units granted on February 10, 2023 converted into 838 shares of common stock at an exercise price of $0.0.

A portion of these shares—309—was automatically withheld at a value of $492.84 per share to cover statutory taxes, leaving 585 shares held directly after the transactions. In addition, 26,649 shares of Intuitive Surgical common stock are reported as held indirectly by a trust associated with the reporting person. The RSU award vests 25% annually over four years, with each vested RSU converting into one share of common stock.

Intuitive Surgical EVP & CFO Jamie Samath reported routine equity compensation activity. On February 10, 2026, 1,077 restricted stock units (RSUs) converted into 1,077 shares of common stock at an exercise price of $0.0, increasing his directly held shares to 8,295 before tax withholding.

On the same date, 496 common shares were withheld at $492.84 per share to cover statutory taxes, leaving 7,799 common shares owned directly afterward. The RSUs vest 25% per year over four years starting on each anniversary of February 10, 2023, with each RSU delivering one share of common stock when it vests, subject to continued service.

Intuitive Surgical EVP Henry L. Charlton reported routine equity compensation activity. On February 10, 2026, 1,077 restricted stock units (RSUs) vested and converted into common shares at $0.0 per share. To cover statutory taxes, 492 shares were surrendered at $492.84 per share, leaving 3,697 common shares held directly and 1,077 RSUs outstanding. The RSU award vests in 25% annual installments on each anniversary of February 10, 2023, contingent on continued service.

Intuitive Surgical executive Mark Brosius reported routine equity compensation activity. On February 10, 2026, 838 restricted stock units granted on February 28, 2023 converted into the same number of common shares at an exercise price of $0.00.

To cover statutory tax withholding, 433 common shares were automatically disposed of at $492.84 per share, leaving Brosius with 592 shares of Intuitive Surgical common stock held directly after the transactions. The RSUs vest in four equal annual installments, each representing 25% of the award.

Intuitive Surgical director Keith R. Leonard reported a change in his holdings of Intuitive Surgical, Inc. common stock. On 01/29/2026, 369 shares of common stock were transferred at a price of $0.0 per share, coded as transaction type "J" for “other.”

The footnote explains this was a transfer of shares pursuant to a divorce decree, indicating a personal, court-directed reallocation rather than an open‑market trade. After this transaction, Leonard beneficially owns 370 shares of Intuitive Surgical common stock in direct form.

Intuitive Surgical executive Mark Brosius reported new performance-based equity awards. On January 28, 2026, he was credited with 2,702 performance stock units tied to a grant dated February 26, 2024 and 5,585 performance stock units tied to a grant dated February 28, 2023.

The company’s compensation committee determined the performance criteria for both awards had been achieved. The 2024-related units are scheduled to vest on February 26, 2027, and the 2023-related units on February 28, 2026, in each case requiring Brosius to remain in continuous service until those vesting dates.

Intuitive Surgical executive Gary Loeb reported performance-based equity awards. On January 28, 2026, he acquired 2,543 performance stock units tied to a February 26, 2024 grant and 2,098 performance stock units tied to a February 28, 2023 grant, each at a stated price of 0.0 per unit.

The company’s compensation committee determined that required performance goals were achieved. The 2023-related units are scheduled to vest on February 28, 2026, and the 2024-related units on February 26, 2027, in each case contingent on Loeb’s continued service with Intuitive Surgical.

Intuitive Surgical’s Chief Executive Officer and director David J. Rosa reported grants of performance stock units that have now been earned based on previously set goals. On January 28, 2026, he acquired 6,360 PSUs from a February 26, 2024 grant, 9,575 PSUs from a February 28, 2023 grant, and 6,034 PSUs from a June 12, 2023 grant.

The compensation committee confirmed that the performance criteria for each grant were achieved. These PSUs convert into common stock if Rosa remains in continuous service through the vesting dates: February 26, 2027 for the 2024 grant and February 28, 2026 for the 2023 and June 2023 grants.

Intuitive Surgical EVP & Chief Medical Officer Myriam Curet reported option and stock transactions plus performance stock units. On January 29, 2026, she exercised 126 non-qualified stock options at $208.9 per share and sold 126 common shares at $520.02 per share under a Rule 10b5-1 trading plan that expires July 29, 2026.

Following these trades, she reported no directly held common stock and 353 common shares held indirectly through a trust. Separately, on January 28, 2026, 5,585 performance stock units granted on February 28, 2023 were reported after the company confirmed performance goals were achieved; these PSUs are scheduled to vest on February 28, 2026, subject to continued service.

Intuitive Surgical director Gary S. Guthart reported new performance-based equity awards. On January 28, 2026, he acquired 8,267 performance stock units (PSUs) tied to a February 26, 2024 grant and 17,556 PSUs tied to a February 28, 2023 grant, each at an exercise price of $0.0.

The Compensation Committee determined that the performance goals for both PSU grants were achieved. The 2024 grant PSUs are scheduled to vest on February 26, 2027, and the 2023 grant PSUs are scheduled to vest on February 28, 2026, in each case if Guthart remains in continuous service to Intuitive Surgical through those dates.

Intuitive Surgical executive Henry L. Charlton, EVP & Chief Commercial and Marketing, reported the achievement of performance conditions for two performance stock unit (PSU) awards. One award covers 2,861 PSUs granted on February 26, 2024, vesting on February 26, 2027, subject to continued service. The second covers 7,182 PSUs granted on February 28, 2023, vesting on February 28, 2026, also conditioned on ongoing employment.

Intuitive Surgical executive Jamie Samath, EVP & CFO & Enterprise Technol, reported performance stock unit awards tied to prior grants. On January 28, 2026, 3,180 PSUs from a February 26, 2024 grant and 7,182 PSUs from a February 28, 2023 grant were credited after performance criteria were achieved.

The 2024 grant PSUs vest on February 26, 2027, and the 2023 grant PSUs vest on February 28, 2026, in each case subject to Samath’s continuous service to Intuitive Surgical through the respective third-anniversary vesting dates.

Intuitive Surgical EVP & Chief Medical Officer Myriam Curet reported option exercises and stock sales in Intuitive Surgical, Inc. common stock. On January 27, 2026, she exercised options for 105 shares at $229.39 and 125 shares at $208.90, then sold 105 shares and 125 shares at $532.61 per share.

The filing notes these trades occurred under a Rule 10b5-1 trading plan that expires on July 29, 2026. After these transactions, the report shows 251 and 1,362 non-qualified stock options remaining directly held and 353 common shares held indirectly by a trust.

Intuitive Surgical director Gary S. Guthart reported an option exercise and related share sales. On January 27, 2026, a non-qualified stock option for 25,500 shares was exercised at $174.2567 per share, increasing his directly held common stock to 28,194 shares.

That same day, 24,500 common shares held directly were sold at a weighted average price of $530.0981, leaving 3,694 directly held shares. In addition, 1,400 shares were sold from a trust for his daughter and 1,400 shares from a trust for his son, each at weighted average prices just above $531, with 15,720 shares remaining in each child’s trust and 1,231,890 shares indirectly held by a separate trust. The filing notes these transactions were carried out under a Rule 10b5-1 trading plan that expires on April 28, 2026.

Intuitive Surgical Inc. reported that a senior officer sold company stock. On 12/15/2025, the SVP & Chief Mfg and Supply Chain Officer sold 464 shares of common stock at a price of $548.49 per share in an open market transaction. After this sale, the officer beneficially owned 131 shares, held directly.

The company notes that the trade was executed under a pre-established Rule 10b5-1 trading plan, which is designed to allow insiders to sell shares according to a predetermined schedule. This plan is stated to comply with SEC Rule 10b5-1 and is scheduled to expire on February 14, 2027.

Intuitive Surgical executive Mark Brosius reported an amended insider transaction showing an open-market sale of 312 shares of Common Stock at $547.36 per share on December 12, 2025. After this sale, he directly owned 595 shares.

The sale was executed under a pre-arranged Rule 10b5-1 trading plan that is scheduled to expire on February 14, 2027. This Form 4/A corrects the third transaction line from his Form 4 filed on December 15, 2025, which had incorrectly reported that transaction’s details, while all other information in the original filing remained accurate.

Intuitive Surgical executive Mark Brosius reported stock option exercises and share sales. As SVP & Chief Manufacturing and Supply Chain, he exercised 4,500 non-qualified stock options for common stock at an exercise price of $79.6378 per share on 12/12/2025, then sold 4,500 common shares that day at $547.36 per share.

He also sold 464 common shares on 12/15/2025 at $548.49 per share. After these transactions, he directly owned 443 shares of Intuitive Surgical common stock and held no remaining derivative securities from the reported option grant. The filing notes that the transactions were made under a Trading Plan that complies with SEC Rule 10b5-1 and expires on February 14, 2027.

Intuitive Surgical (ISRG) executive Henry L. Charlton reported option exercises and open‑market sales on 11/12/2025 under a Rule 10b5‑1 trading plan. He exercised options for 636, 2,565, 2,898, and 2,901 shares at exercise prices of $347.4167, $245.6, $242.3367, and $177.9867, respectively, and reported multiple sales at $580 per share. Following the transactions, he directly owns 3,056 shares. The plan is stated to expire on June 1, 2026.

Intuitive Surgical (ISRG): Form 4 insider transaction. Director Craig H. Barratt exercised 750 stock options at $71.3233 and sold 750 common shares at $580 on 11/12/2025 under a Rule 10b5-1 trading plan.

Following these transactions, directly held common stock was 0. An additional 27,198 shares were reported as indirectly owned by a trust. The reported option was a non-qualified stock option; the derivative position shown was 0 after the exercise.

Intuitive Surgical (ISRG): Director transaction reported. Director Keith Leonard filed a Form 4 for a gift of 1,606 shares of common stock on 11/12/2025 (transaction code G) at a stated price of $0.0. The filing notes the shares were gifted to a CRUT.

Following the transaction, the reporting person’s beneficial ownership stands at 739 shares, held directly. This is a personal, non-cash transfer and does not reflect a sale in the market.

Intuitive Surgical (ISRG) executive transaction: EVP & Chief Medical Officer Myriam Curet exercised 105 stock options at $229.39 and, on the same day (11/10/2025), sold 105 common shares at $560 under a Rule 10b5-1 trading plan.

Following these transactions, she reported 0 shares held directly, 353 shares held indirectly by a trust, and 1,571 non-qualified stock options remaining outstanding (expiration 02/27/2030).

Intuitive Surgical (ISRG) reported insider activity by EVP & Chief Digital Officer Brian Miller. On 11/10/2025, he exercised options for 1,298 shares at $229.39 and 2,202 shares at $208.90, then sold the same 3,500 shares at $575.00 per share under a Rule 10b5-1 trading plan that expires on December 10, 2025. Following these transactions, he directly owned 5,758 common shares. Remaining derivative holdings included 2,115 and 6,602 non-qualified stock options from prior grants, subject to stated vesting schedules.

Intuitive Surgical (ISRG) reported an insider transaction by its VP Corporate Controller. On 11/05/2025, the officer exercised non-qualified stock options for 1,908 shares at $76.9989 and 159 shares at $59.4622, then sold the same amounts at $550 per share pursuant to a Rule 10b5-1 trading plan. Following these transactions, direct beneficial ownership stood at 473 common shares. The options exercised were granted under the 2010 Incentive Award Plan, with vesting schedules as disclosed.

Intuitive Surgical (ISRG) CEO and Director David J. Rosa reported an insider gift of 5,454 shares of common stock on 11/03/2025, coded G for gift at $0.0 per share. Following the transaction, he directly holds 228,802 shares. The filing notes the shares were gifted to The Rosa Donor Advised Fund.

Intuitive Surgical (ISRG) insider activity: EVP & Chief Medical Officer Myriam Curet reported option exercises and open‑market sales under a Rule 10b5‑1 trading plan. On 10/28/2025, she exercised 5,030 options at $242.3367, 1,153 at $229.39, and 1,379 at $208.9, then sold the corresponding shares at a weighted average price of $548.4254. On 10/29/2025, she exercised 125 options at $208.9 and sold those shares at $543.

After these transactions, direct holdings were 0 shares; indirect holdings were 353 shares held by a trust. Footnotes note the plan expires July 29, 2026 and provide vesting schedules under the company’s 2010 Incentive Award Plan.

Intuitive Surgical (ISRG) insider Gary S. Guthart, Executive Chair and Director, reported insider transactions on 10/24/2025. He exercised 36,000 non-qualified stock options at an exercise price of $109.4856 and sold shares the same day under a prearranged plan.

Dispositions included 28,800 shares at a weighted average price of $547.5571, plus additional sales of 1,400 shares at $546.3499 and 1,400 shares at $546.184. The filing states the trades were made under a Rule 10b5-1 trading plan that expires on April 28, 2026, with sale price ranges and undertakings to provide full breakdowns upon request.

Intuitive Surgical (ISRG): Director transaction disclosed. Director Craig H. Barratt exercised a non-qualified stock option for 2,193 shares at an exercise price of $71.3233 on 10/24/2025 and sold 2,193 shares at $548.01 the same day under a Rule 10b5-1 trading plan.

Following the transactions, direct common stock holdings were 0 shares, and indirect holdings were 27,198 shares held by a trust. The filing also reports 750 derivative securities (options) remaining beneficially owned directly. The trading plan complies with Rule 10b5-1 and expires on April 29, 2026. The option was granted under the Non-Employee Directors' Stock Option Plan with vesting as noted in the plan terms.

Intuitive Surgical (ISRG) CEO David J. Rosa reported insider transactions on 10/24/2025. He exercised 27,000 non-qualified stock options at an exercise price of $79.6378 per share and sold 24,500 shares of common stock at a weighted average price of $547.5502.

The sales were executed under a Rule 10b5-1 trading plan that expires on June 11, 2026, with individual trade prices ranging from $542.16 to $550.21. Following these transactions, Rosa beneficially owns 234,256 shares directly. The exercised option, granted under the 2010 Incentive Award Plan, carries an expiration date of 02/15/2027 and vested per a stated schedule.

Gary Loeb, EVP & Chief Legal and Compliance at Intuitive Surgical (ISRG), reported beneficial ownership changes on 10/10/2025. A vesting event converted 2,612 restricted stock units into common shares (transaction code M), with net shares deposited after withholding for taxes. Immediately following the vesting, the filing shows a sale/disposition of 1,296 shares at $443.76 (transaction code F), leaving the reporting person with 3,561 shares beneficially owned. The RSU grant vests 25% annually over four years, and the filing notes that 25% of the grant was released at this vesting date.